...
SDPA DIGITAL Live Blog: What’s New in the Literature?
October 29, 2020

Dr. Joslyn Kirby kicked off the SDPA Digital CME conference Thursday morning with an enlightening review of the dermatology medical literature published within the last year.  Dr. Kirby initiated the presentation by illustrating the dermatologic manifestations of COVID-19 with an important reminder that these cutaneous presentations are  “not pathognomonic to COVID.”  Additionally, she reviewed the

...
Platelet-rich Plasma for Alopecia Areata
September 8, 2020

Alopecia Areata (AA) is a common autoimmune disease that causes hair loss of the scalp, face, and other areas of the body. According to the National Alopecia Areata Foundation, 6.8 million individuals in the US are affected by AA.  Patchy, or focal, alopecia is the most common presentation of AA and typically presents with coin-sized

...
Managing Hair Loss Without Losing Your Own
November 20, 2019

Joslyn Kirby, MD sits down with Dermcast.tv for discussion about the management of the alopecia patient.  Hair, or lack thereof,  can be a direct measure of attractiveness.  Alopeica patients often struggle with the stigma associated with their hair loss. Dr. Kirby talks about using dermoscopy in the treatment process, and covers the different treatment options

...
PRP/Microneedling

Faculty: Jennifer Holman, MD Dr. Holman began her presentation on platelet rich plasma (PRP) and microneedling through emphasizing her belief in the utilization of PAs in her practice as “best working as partners”. She reviewed the use of PRP dating back to the 1970s in medicine. The benefit of PRP is the 300+ active substances

...
Does Microneedling with Platelet-Rich Plasma Injections Improve Androgenic Alopecia?
July 10, 2018

Androgenic alopecia (AGA) is typically treated with a combination of finasteride and minoxidil, which targets androgens, but even with this treatment 40% of patients go bald. A recent study used dermoscopy to evaluate the effectiveness of using microneedling in combination with injections of platelet-rich plasma (PRP) as a treatment modality. Twenty patients participated in the